0.5988
前日終値:
$0.6204
開ける:
$0.61
24時間の取引高:
2.40M
Relative Volume:
1.35
時価総額:
$47.96M
収益:
$101.21M
当期純損益:
$-569.00K
株価収益率:
-29.94
EPS:
-0.02
ネットキャッシュフロー:
$-56.88M
1週間 パフォーマンス:
-2.67%
1か月 パフォーマンス:
-24.63%
6か月 パフォーマンス:
-52.10%
1年 パフォーマンス:
-72.15%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
名前
Cytomx Therapeutics Inc
セクター
電話
650.515.3185
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CTMX
Cytomx Therapeutics Inc
|
0.5988 | 47.96M | 101.21M | -569.00K | -56.88M | -0.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-05-28 | アップグレード | Piper Sandler | Neutral → Overweight |
2024-05-09 | アップグレード | Wedbush | Neutral → Outperform |
2024-05-06 | アップグレード | Jefferies | Hold → Buy |
2024-04-22 | アップグレード | JP Morgan | Underweight → Neutral |
2022-11-14 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2022-07-07 | ダウングレード | Jefferies | Buy → Hold |
2022-07-07 | ダウングレード | Mizuho | Buy → Neutral |
2022-07-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
2022-07-07 | ダウングレード | Wedbush | Outperform → Neutral |
2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
2022-01-18 | アップグレード | Barclays | Underweight → Overweight |
2021-11-15 | 開始されました | BTIG Research | Buy |
2021-05-28 | ダウングレード | Barclays | Equal Weight → Underweight |
2021-03-29 | 開始されました | JP Morgan | Overweight |
2021-03-23 | アップグレード | Jefferies | Hold → Buy |
2020-09-22 | ダウングレード | Guggenheim | Buy → Neutral |
2020-06-01 | ダウングレード | Jefferies | Buy → Hold |
2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
2020-03-24 | アップグレード | Wedbush | Neutral → Outperform |
2020-03-04 | 開始されました | Barclays | Equal Weight |
2019-11-20 | 開始されました | Guggenheim | Buy |
2019-11-11 | ダウングレード | Wedbush | Outperform → Neutral |
2019-06-13 | 開始されました | Mizuho | Buy |
2019-05-14 | 開始されました | Cantor Fitzgerald | Overweight |
2019-03-11 | 開始されました | Barclays | Overweight |
2018-11-26 | 開始されました | Piper Jaffray | Overweight |
2018-10-15 | 開始されました | Goldman | Neutral |
2018-09-13 | 開始されました | H.C. Wainwright | Buy |
2018-06-01 | 開始されました | SunTrust | Buy |
2018-01-05 | 開始されました | Citigroup | Buy |
2017-09-08 | 開始されました | Wedbush | Outperform |
2017-03-27 | 開始されました | H.C. Wainwright | Buy |
2017-03-02 | 開始されました | Instinet | Buy |
2017-01-03 | ダウングレード | Oppenheimer | Outperform → Perform |
2015-11-02 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Cytomx Therapeutics Inc (CTMX) 最新ニュース
CytomX at Barclays Healthcare: Probody Platform Progress - Investing.com India
CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News
CytomX Therapeutics (NASDAQ:CTMX) Upgraded by StockNews.com to “Buy” Rating - Defense World
What Are You Thinking About Investing In CytomX Therapeutics Inc (NASDAQ: CTMX) Stock? - Stocks Register
CytomX Therapeutics’ (CTMX) Outperform Rating Reiterated at Wedbush - Defense World
Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue - Investing.com India
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Brokerages - Armenian Reporter
CytomX Therapeutics’ (CTMX) “Neutral” Rating Reiterated at HC Wainwright - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call Transcript - Insider Monkey
CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability - TipRanks
CytomX Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now - Insider Monkey
Deal Watch: Amgen, CytomX Pull Back On Part Of T-Cell Engager Collaboration - Citeline News & Insights
Cautious Outlook for CytomX Therapeutics Amid Pipeline Challenges and Strategic Setbacks - TipRanks
CytomX stock plunges to 52-week low, touches $0.6 By Investing.com - Investing.com Canada
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Insights - GuruFocus.com
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
CytomX Therapeutics Inc earnings beat by $0.43, revenue topped estimates - Investing.com South Africa
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
CytomX Therapeutics Reports Strong 2024 Financial Results - TipRanks
CytomX To Report Colorectal Cancer Trial Data Of CX-2051 In 1H, 2025 - Nasdaq
CytomX Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue By Investing.com - Investing.com UK
CYTOMX THERAPEUTICS Earnings Results: $CTMX Reports Quarterly Earnings - Nasdaq
CytomX Therapeutics Inc Reports Q4 EPS of $0.38 and Revenue of $138.1 Million, Surpassing Estimates - GuruFocus.com
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update - The Manila Times
CytomX Therapeutics Advances CX-2051 and CX-801 Programs, Reports Strengthened Financial Position - Nasdaq
CytomX stock plunges to 52-week low, touches $0.6 - Investing.com India
Daily Progress: CytomX Therapeutics Inc (CTMX) Drop -5.76, Closing at 0.62 - The Dwinnex
10 Cheap Growth Stocks to Buy Now - Insider Monkey
CytomX Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect? - MSN
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference - The Manila Times
Can CytomX's Conference Presentation Reveal New Strategic Directions for Its Masked Biologics Platform? - StockTitan
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q4 202 - GuruFocus.com
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q4 2024 Result - Yahoo Finance
CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday - Defense World
CytomX Therapeutics (NASDAQ:CTMX) Stock Crosses Below Fifty Day Moving AverageShould You Sell? - MarketBeat
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - The Manila Times
When Will CytomX Release Q4 2024 Results? Key Date for Biotech Investors - StockTitan
CytomX faces Nasdaq delisting over share price woes - Investing.com India
CytomX faces Nasdaq delisting over share price woes By Investing.com - Investing.com South Africa
CytomX stock hits 52-week low at $0.74 amid market challenges - Investing.com Nigeria
CytomX stock hits 52-week low at $0.74 amid market challenges By Investing.com - Investing.com South Africa
Cytomx Therapeutics Inc (CTMX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):